source
- RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer dataRevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
- Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory marketAnalysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…BioSpace · 58m agoDealPositive